Serosurveillance among COVID-19 Cases in Ahmedabad Using SARS-COV2 IgG Antibodies

Authors

  • Om Prakash Deputy Municipal Commissioner, Ahmedabad Municipal Corporation
  • Bhavin Solanki Medical Officer of Health, Ahmedabad Municipal Corporation
  • Jay Sheth AMC MET Medical College, Ahmedabad, Gujarat https://orcid.org/0000-0002-9598-4473
  • Daxa Maitrak Deputy Health Officer, Ahmedabad Municipal Corporation
  • Mina Kadam AMC MET Medical College, Ahmedabad, Gujarat
  • Sheetal Vyas AMC MET Medical College, Ahmedabad, Gujarat https://orcid.org/0000-0002-2756-6608
  • Aparajita Shukla Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ahmedabad, Gujarat https://orcid.org/0000-0001-5432-8026
  • Hemant Tiwari Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ahmedabad, Gujarat https://orcid.org/0000-0002-0379-7479

DOI:

https://doi.org/10.47203/IJCH.2021.v33i02.022

Keywords:

COVID-19 cases, Immunity, IgG Antibodies, SARS-CoV2, Seroprevalence

Abstract

Background: Serosurveillance study focusing on antibodies against SARS-CoV2 among the Covid19 cases can add value in the scientific knowledge & help in formulating valid predictions regarding immunity status in the post-covid period. Objectives: To estimate seropositivity among covid19 cases and to identify various factors affecting seropositivity. Methods: During second half of October 2020, a population based serosurvey on Covid19 cases was carried out in Ahmedabad. Covid-Kavach test kits were used and estimated seroprevalence was compared with available demographic and covid19 case related parameters to identify factors affecting seropositivity in the post-covid period. Simple proportions and Z-test were used as appropriate. Results: As on October 2020, the sero-positivity among Covid19 cases in Ahmedabad was 54.51% [95% Confidence Interval (CI) 52.14-56.86%]. Females have higher positivity (54.78%) as compared to males (54.30%) but the difference was statistically not significant (Z=0.19, P=0.84). Among children and elderly, the positivity is high and from young adults to elderly the seropositivity has an increasing trend. Severity of clinical illness and longer duration of hospitalization are associated with higher seropositivity. Conclusion: With 54.51% seropositivity among covid19 cases, it is clear that all the covid19 cases may not have developed IgG antibodies, have undetectable level or might have disappeared during the post-covid period. Comparison of seropositivity with age group and clinical case details clearly suggest close correlation with the severity of clinical symptoms. The seronegative cases indicate the need for further in-depth scientific research to identify the factors affecting immunity and to uncover the reasons behind the same.

Downloads

Download data is not yet available.

References

Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. N Engl J Med. 2020;382(8):692-694

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K., Lau, E., Wong, J. Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., Tu, W., … Feng, Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine, 382(13), 1199–1207.

GeurtsvanKessel, C. H., Okba, N., Igloi, Z., Bogers, S., Embregts, C., Laksono, B. M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J., van den Akker, J., van Kampen, J., van der Eijk, A. A., van Binnendijk, R. S., Haagmans, B., & Koopmans, M. (2020). An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nature communications, 11(1), 3436. https://doi.org/10.1038/s41467-020-17317-y

World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for COVID-19 virus infection, 17 March 2020. World Health Organization; 2020.

Hanage, William, XuetingQiu, Lee Kennedy-Shaffer. Snowball Sampling Study Design for Serosurveys in the Early COVID-19 Pandemic (2020). Available from: https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37363145(Accessed on 25.06.2021)

Cohen J. Unprecedented nationwide blood studies seek to track U.S. coronavirus spread. Science. 2020 Apr 7 Available from: https://www.sciencemag.org/news/2020/04/unprecedented-nationwide-blood-studies-seek-track-us-coronavirus-spread (Accessed on 25.06.2021)

Xu, X., Sun, J., Nie, S. et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med 26, 1193–1195 (2020). https://doi.org/10.1038/s41591-020-0949-6

Murhekar M V, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Wesley Vivian Thangaraj J, et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian J Med Res. 2020;152:48–60. DOI: 10.4103/ijmr.IJMR_3290_20 PMID: 32952144 PMCID: PMC7853249

World Health Organization. Public health surveillance for COVID-19: interim guidance, 7 August 2020 [Internet]. Geneva; 2020 Aug. Available from: https://apps.who.int/iris/bitstream/handle/10665/333752/WHO-2019-nCoV-SurveillanceGuidance-2020.7-eng.pdf?sequence=1&isAllowed=y(Accessed on 25.06.2021)

Sapkal G, Shete-Aich A, Jain R, et al. Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG. Indian J Med Res. 2020;151(5):444-449. doi:10.4103/ijmr.IJMR_2232_20 PMID: 32611915 PMCID: PMC7530443

Chirathaworn C, Sripramote M, Chalongviriyalert P, et al. SARS-CoV-2 RNA shedding in recovered COVID-19 cases and the presence of antibodies against SARS-CoV-2 in recovered COVID-19 cases and close contacts, Thailand, April-June 2020. PLoS One. 2020;15(10):e0236905. Published 2020 Oct 29. doi:10.1371/journal.pone.0236905 PMID: 33119712 PMCID: PMC7595404

Martinez-Fierro, M. L., Ríos-Jasso, J., Garza-Veloz, I., Reyes-Veyna, L., Cerda-Luna, R. M., Duque-Jara, I., Galvan-Jimenez, M., Ramirez-Hernandez, L. A., Morales-Esquivel, A., Ortiz-Castro, Y., Gutierrez-Camacho, J. R., Valdes-Aguayo, J. J., & Vargas-Rodriguez, J. R. (2021). The role of close contacts of COVID-19 patients in the SARS-CoV-2 transmission: an emphasis on the percentage of nonevaluated positivity in Mexico. American journal of infection control, 49(1), 15–20. https://doi.org/10.1016/j.ajic.2020.10.002

Bryant JE, Azman AS, Ferrari MJ, et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Sci Immunol. 2020;5(47):eabc6347. doi:10.1126/sciimmunol.abc6347 PMID: 32430309

Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-319. doi:10.1016/S0140-6736(20)31304-0 PMID: 32534626 PMCID: PMC7289564

Wang, X., Guo, X., Xin, Q., Pan, Y., Hu, Y., Li, J., Chu, Y., Feng, Y., & Wang, Q. (2020). Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71(10), 2688–2694. https://doi.org/10.1093/cid/ciaa721

Hu WT, Howell JC, Ozturk T, et al. Antibody Profiles According to Mild or Severe SARS-CoV-2 Infection, Atlanta, Georgia, USA, 2020. Emerg Infect Dis. 2020;26(12):2974-2978. doi:10.3201/eid2612.203334 doi: 10.3201/eid2612.203334 PMID: 32857691 PMCID: PMC7706962

Okba NMA, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020;26(7):1478-1488. doi:10.3201/eid2607.200841 PMID: 32267220 PMCID: PMC7323511

Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791-797. doi:10.1099/jgv.0.001439 PMID: 32430094 PMCID: PMC7641391

Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021;147(2):545-557.e9. doi:10.1016/j.jaci.2020.10.040 PMID: 33221383 PMCID: PMC7677074

Nikolai, L. A., Meyer, C. G., Kremsner, P. G., &Velavan, T. P. (2020). Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible. International journal of infectious diseases: IJID : official publication of the International Society for Infectious Diseases, 100, 112–116. https://doi.org/10.1016/j.ijid.2020.08.076

Yongchen Z, Shen H, Wang X, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):833-836. doi:10.1080/22221751.2020.1756699 PMID: 32306864 PMCID: PMC7241531

Wellinghausen, N., Plonné, D., Voss, M., Ivanova, R., Frodl, R., & Deininger, S. (2020). SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 130, 104542. https://doi.org/10.1016/j.jcv.2020.104542

Downloads

Published

2021-06-30

How to Cite

1.
Prakash O, Solanki B, Sheth J, Maitrak D, Kadam M, Vyas S, et al. Serosurveillance among COVID-19 Cases in Ahmedabad Using SARS-COV2 IgG Antibodies. Indian J Community Health [Internet]. 2021 Jun. 30 [cited 2024 Dec. 22];33(2):351-6. Available from: https://iapsmupuk.org/journal/index.php/IJCH/article/view/2115

Issue

Vol. 33 No. 2 (2021)

Section

Original Article

Dimensions Badge

License

Copyright (c) 2021 Indian Journal of Community Health

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.